Programm                 "Degeneration und Regeneration– Grundlagen, Diagnostik und Therapie"


Hotelbuchung
   Hotel Registration
Grußwort
   Welcome address
Beteiligte Gesellschaften
   Societies involved
DOG Information
   DOG Information
Eröffnung des Kongresses
   Opening Ceremony
Preise
   Awards
Ablauf der Tagung 2003
   General overview of congress
Lageplan der Räumlichkeiten
   Map of Congress Center
Wissenschaftliche Themen
   Scientific topics
Symposien
   Symposia
Wissenschaftliches Programm
   Scientific program
Posterpräsentationen
   Poster Presentation
Kurse
   Courses
Begleitende Veranstaltungen
   Accompanying program
Arbeitssitzungen
   Working sessions
Rahmenprogramm
   Social program
Allgemeine Informationen
   General Information
Autorenindex
   Index of Authors
Industrieaussteller
   Commercial exhibitors
Sponsoren
   Sponsors
Impressum



DOG Homepage


Abstract
Abstract

Pharmacology and molecular biology of myopia - possibilities for pharmacological intervention

Feldkaemper M.
Section of Neurobiology of the Eye, University Eye Hospital, Dept. II, Tübingen

Purpose: Since retinal image processing determines the release of growth controlling messengers from the retina to the underlying sclera, the search for agents that could lead to an inhibition of scleral expansion during myopia development is a promising research direction.
Method: Drugs were applied intravitreally (chicks) or by an ophthalmic gel (children). Myopia was induced by deprivation or defocus and eye growth was compared in saline-treated and drug-treated eyes (chicks). Differential Display (DD-RT-PCR, chicks) was used to search for retinal genes that are controlled by imposed defocus. The search for areas in the genome that affect eye size was done by quantitative trait loci (QTL) mapping (mice) or transmission disequilibrium testing (TDT) (humans).
Results: Atropine, an unspecific muscarinic antagonist that has been tested in animal models and children, is currently the most successful drug for myopia inhibition. At least four potential routes for atropine action are known although it is still uncertain whether it acts through muscarinic receptors at all. Pirenzepine, a preferential M1/M4 antagonist is in clinical phase II studies and is said to reduce progression by 50%, although only in the first year of application (applied twice a day, as an ophthalmic gel). Moreover, dopamine agonists, opiate and VIP antagonists can inhibit myopia but these drugs and neuro


Zurück | Back